Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Ralimetinib
Другие языки:

    Ralimetinib

    Подписчиков: 0, рейтинг: 0
    Ralimetinib
    Ralimetinib.png
    Ralimetinib structural formula
    Clinical data
    Other names LY2228820
    Routes of
    administration    		 PO
    ATC code
    • none
    Identifiers
    • 5-[2-tert-Butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C24H29FN6
    Molar mass 420.536 g·mol−1
    3D model (JSmol)
    • C12C(=CC=C(N=1)C1=C(N=C(N1)C(C)(C)C)C1C=CC(=CC=1)F)N=C(N2CC(C)(C)C)N
    • InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)
    • Key:XPPBBJCBDOEXDN-UHFFFAOYSA-N

    Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. It is a p38 mitogen-activated protein kinase inhibitor.

    A phase II trial for treatment of ovarian cancer has completed.


    Новое сообщение